Biotech & pharma press releases — Press Release Database

Finance · Biotech & pharma

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (SPRY) Investors with Losses to Contact the Firm Before October 5, 2026

New York, New York--(August 24, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by...

Aug 24 · 13:35Newsfile

Healthcare · Biotech & pharma

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

Executive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models. Pitts to moderate expert sessions on Translational Pharmaceutical Innovation and the Emerging...

Aug 24 · 12:15PR Newswire

Finance · Food & drink

Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Roblox Corporation (NYSE: RBLX); Symbotic Inc. (NASDAQ: SYM); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your Behalf

NOTICE: ARS Pharmaceuticals Inc. (NASDAQ: SPRY); Roblox Corporation (NYSE: RBLX); Symbotic Inc. (NASDAQ: SYM); The Simply Good Foods Company (NASDAQ: SMPL)

Aug 24 · 12:03GlobeNewswire

Healthcare · Real estate

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA introduces a dedicated regulatory structure for psychedelic drug development, including MDMA

Aug 24 · 12:03GlobeNewswire

Biotech & pharma

Connecticut Office of the Attorney General: If You Bought Certain Generic Prescription Drugs in the United States

You Could Get Money from Current and Future Settlements HARTFORD, Conn., Aug. 24, 2026 -- An additional settlement has been reached with some generic prescription drug manufacturers in lawsuits alleging that consumers paid artificially inflated prices for generic prescription...

Aug 24 · 12:00PR Newswire

Healthcare · Automotive

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Aug 24 · 12:00GlobeNewswire

Healthcare · Food & drink

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –

Aug 24 · 12:00GlobeNewswire

Finance · Healthcare

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

BOSTON, Aug. 24, 2026 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.

Aug 24 · 12:00GlobeNewswire

Biotech & pharma

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --

Aug 24 · 12:00GlobeNewswire

Healthcare · Biotech & pharma

QurAlis to Participate in Upcoming Investor Conferences in September

CAMBRIDGE, Mass., August 24, 2026--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in September. Management will also participate in one-on-one investor meetings.

Aug 24 · 11:45Business Wire

Finance · Biotech & pharma

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

SAN DIEGO, August 24, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU).

Aug 24 · 07:01Business Wire

Biotech & pharma

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio

TOKYO, August 24, 2026--Daiichi Sankyo (TSE: 4568) has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company’s oncology and specialty medicine business through a new globally integrated Commercialization Unit, effective April 1, 2027.

Aug 24 · 07:00Business Wire